{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:36Z","timestamp":1787721636657,"version":"build-2784847793"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal locoregional treatment for recurrent hepatocellular carcinoma (rHCC) in the era of potent systemic therapy remains undefined. This study aimed to compare the efficacy, safety, and resource consumption of transarterial chemoembolization combined with radiofrequency ablation (TACE-RFA) versus TACE or RFA monotherapy, specifically when administered on a uniform background of systemic therapy (Lenvatinib plus PD-1 inhibitors).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 243 patients with rHCC who met strict eligibility criteria (tumor size 3.0\u20137.0 cm, \u22643 recurrent nodules, and preserved liver function, corresponding to Barcelona Clinic Liver Cancer (BCLC) A\/B and China Liver Cancer (CNLC) Ia\u2013IIa stages. Crucially, all included patients uniformly received standardized peri-procedural systemic therapy (Lenvatinib and Tislelizumab). Based on the actual locoregional strategies, the cohort was divided into TACE-RFA (n=56), TACE alone (n=114), or RFA alone (n=73) groups. To mitigate selection bias, 1:1 propensity score matching (PSM) was employed, generating two matched cohorts: Combination vs. TACE alone (54 pairs) and Combination vs. RFA alone (54 pairs). Survival outcomes, post-procedural pain, hospital stay, and costs were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, baseline characteristics were well-balanced. The median progression-free survival (PFS) in the combination group was 21.4 months, significantly superior to the matched TACE monotherapy cohort (13.5 months, P &amp;lt; 0.001) and the independently matched RFA monotherapy cohort (10.4 months, P &amp;lt; 0.001). Overall survival (OS) showed no significant differences among the groups (median OS 48.9\u201350.5 months, all P &amp;gt; 0.05), likely because the uniform administration of potent systemic therapy drastically prolonged the baseline survival for all patients, thereby diluting the OS advantage of local control. Safety profiles were comparable across all modalities (P &amp;gt; 0.05). Predictably, combination therapy incurred longer median hospital stays and higher total costs compared to monotherapies (all P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For rHCC patients receiving concurrent Lenvatinib and PD-1 inhibitors, sequential TACE-RFA therapy provides a profound and independent progression-free survival benefit over locoregional monotherapies without increasing patient discomfort. The superior local tumor control justifies the anticipated initial increases in perioperative resource consumption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1825546","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:08Z","timestamp":1787719568000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of TACE-RFA versus monotherapies on a background of systemic therapy for recurrent hepatocellular carcinoma: a propensity score-matched analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wendi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"Ningbo University Health Science Center","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"Ningbo University Health Science Center","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfa","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.921667","article-title":"Contrast agents for hepatocellular carcinoma imaging: value and progression","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis","volume":"10","author":"Roayaie","year":"2004","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2262012198","article-title":"Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study","volume":"226","author":"Livraghi","year":"2003","journal-title":"Radiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S497956","article-title":"Multicenter study on transarterial chemoembolization combined with radiofrequency ablation for early-stage hepatocellular carcinoma: primary versus recurrent HCC","volume":"11","author":"Chen","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.241096","article-title":"Transarterial chemoembolization with radiofrequency ablation versus surgical resection for small late-recurrence hepatocellular carcinoma","volume":"314","author":"Zhang","year":"2025","journal-title":"Radiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-02968-1","article-title":"CIRSE standards of practice on hepatic transarterial chemoembolisation","volume":"44","author":"Lucatelli","year":"2021","journal-title":"Cardiovasc Interventional Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-022-03233-9","article-title":"Initiative on superselective conventional transarterial chemoembolization results (INSPIRE)","volume":"45","author":"de Baere","year":"2022","journal-title":"Cardiovasc Interventional Radiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-020-02471-z","article-title":"CIRSE standards of practice on thermal ablation of liver tumours","volume":"43","author":"Crocetti","year":"2020","journal-title":"Cardiovasc Interventional Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000580","article-title":"Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model","volume":"94","author":"Pillai","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10081634","article-title":"Principles of and advances in percutaneous ablation","volume":"258","author":"Ahmed","year":"2011","journal-title":"Radiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25314","article-title":"Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization","volume":"116","author":"Morimoto","year":"2010","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.713432","article-title":"Transarterial chemoembolization combined with radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma after curative resection: a 10-year single-center comparative study","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.2366","article-title":"Transarterial chemoembolization plus thermal ablation in unresectable hepatocellular carcinoma: the phase 3 TORCH randomized clinical trial","author":"Lyu","year":"2026","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40644-023-00534-1","article-title":"Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma","volume":"23","author":"Bi","year":"2023","journal-title":"Cancer Imaging: Off Publ Int Cancer Imaging Soc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108926","DOI":"10.1016\/j.jvir.2026.108926","article-title":"Radiation segmentectomy versus combined chemoembolization plus microwave ablation: histopathologic tumor necrosis in hepatocellular carcinoma measuring up to 5 cm","author":"Yu","year":"2026","journal-title":"J Vasc Interv Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03080-1","article-title":"Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials","volume":"46","author":"Yu","year":"2021","journal-title":"Abdom Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:22Z","timestamp":1787719582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1825546"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1825546","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1825546"}}